Race Oncology Limited (“Race”) announces Executive Director and Chief Scientific Officer (CSO), Dr Daniel Tillett has advised his decision to step down from his roles. Dr Tillett will provide ongoing support through June 2023 to ensure a smooth transition of his CSO responsibilities to the Race team, with oversight from Professor Tim Hammond, who will assume the role of Interim CSO. 

The following video supports the full announcement.